Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol

Pharmacotherapy

Volumn 31, Issue 7, 2011, Pages 630-641

  Parker, Robert B ^a   Soberman, Judith E ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

CYP2D6; Cytochrome P450 isoenzyme; Metoprolol; Paroxetine; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALPHA HYDROXYMETOPROLOL; ATENOLOL; CYTOCHROME P450 2D6; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PAROXETINE;

ADULT; AKATHISIA; ALLELE; AREA UNDER THE CURVE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MEASUREMENT; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG URINE LEVEL; ENANTIOMER; EXTENDED RELEASE PREPARATION; FATIGUE; FEMALE; GENOTYPE; HEART RATE; HUMAN; HUMAN EXPERIMENT; IMMEDIATE RELEASE PREPARATION; INSOMNIA; ISOMER; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEART RATE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PAROXETINE; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; YOUNG ADULT;

EID: 79959785159     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.7.630     Document Type: Article

References (47)

1. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 1983;34:732-7. (Pubitemid 14219918)
2. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996;24:350-5. (Pubitemid 26087089)
3. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009;48:689-723.
4. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med 1982;307:1558-60. (Pubitemid 13245431)
5. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465-72. (Pubitemid 34913529)
6. Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000;67:466-77. (Pubitemid 30327485)
7. Sharma A, Pibarot P, Pilote S, et al. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther 2005;313:1172-81. (Pubitemid 40727020)
8. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305-15. (Pubitemid 38668397)
9. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527-37. (Pubitemid 44528168)
10. O'Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008;168:2232-7.
11. Frasure-Smith N, Lesperance F, Habra M, et al. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation 2009;120:134-40.
12. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9. (Pubitemid 34848222)
13. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol 2010;56:692-9.
14. Hemeryck A, De Vriendt CA, Belpaire FM. Metoprololparoxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction. Drug Metab Dispos 2001;29:656-63. (Pubitemid 32374566)
15. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 2000;67:283-91. (Pubitemid 30176387)
16. Lucker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990;30:S17-27.
17. Oosterhuis B, Jonkman J, Zuiderwijk P, Sollie F. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation. J Clin Pharmacol 1990;30:S33-8.
18. Wikstrand J, Andersson B, Kendall MJ, Stanbrook H, Klibaner M. Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. J Cardiovasc Pharmacol 2003;41:151-7. (Pubitemid 36135237)
19. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993;341:967-8.
20. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-97. (Pubitemid 26382973)
21. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine oxidation polymorphism: population and family studies. Br J Clin Pharmacol 1985;20:555-66. (Pubitemid 16184094)
22. Herring VL, Bastian TL, Lalonde RL. Solid-phase extraction and direct high-performance liquid chromatographic determination of metoprolol enantiomers in plasma. J Chromatogr 1991;567:221-7.
23. Fang J, Semple HA, Song J. Determination of metoprolol, and its four metabolites in dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004;809:9-14. (Pubitemid 38998413)
24. Seeringer A, Brockmoller J, Bauer S, Kirchheiner J. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. Eur J Clin Pharmacol 2008;64:883-8.
25. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55. (Pubitemid 23153452)
26. Funck-Brentano C, Kroemer HK, Pavlou H, Woosley RL, Roden DM. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 1989;27:435-44. (Pubitemid 19101150)
27. 2-receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther 1991;256:959-66.
28. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008;64:275-82.
29. Sandberg A, Abrahamsson B, Regardh CG, Wieselgren I, Bergstrand R. Pharmacokinetic and biopharmaceutic aspects of once-daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990;30:S2-16.
30. Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Discordant β-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy 2006;26:1247-54. (Pubitemid 44306884)
31. Dargie HJ. β-Blockers in heart failure. Lancet 2003;362:2-3.
32. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988; 33(suppl):S9-14.
33. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment - a science advisory from the American Heart Association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American Psychiatric Association. Circulation 2008;118: 1768-75.
34. Summers KM, Martin KE, Watson K. Impact and clinical management of depression in patients with coronary artery disease. Pharmacotherapy 2010;30:304-22.
35. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000;40:58-66.
36. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002;22:169-73. (Pubitemid 34292489)
37. Bijl MJ, Visser LE, van Schaik RH, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users. Clin Pharmacol Ther 2009;85:45-50.
38. Rau T, Wuttke H, Michels LM, et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009;85:269-72.
39. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429-37. (Pubitemid 35178868)
40. Fux R, Morike K, Prohmer AM, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005;78:378-87. (Pubitemid 41393673)
41. Zineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004;76:536-44. (Pubitemid 39601544)
42. Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004;76:302-12. (Pubitemid 39313120)
43. 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. J Clin Pharmacol 1990;30: S46-54.
44. Shin J, Johnson JA. Pharmacogenetics of β-blockers. Pharmacotherapy 2007;27:874-87.
45. 1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003;74:372-9.
46. Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Influence of phenotype and pharmacokinetics on β-blocker drug target pharmacogenetics. Pharmacogenomics J 2006;6:174-8. (Pubitemid 43811568)
47. Sofowora GG, Dishy V, Muszkat M, et al. A common β1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin Pharmacol Ther 2003;73:366-71. (Pubitemid 36403596)